Ascendant Capital Management’s Exact Sciences EXAS Stock Holding History

Ascendant Capital Management’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$712K	Buy	+10,500	New	+$675K	0.94%	45

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Ascendant Capital Management's EXAS Position: Q1 2023 in Review

Ascendant Capital Management opened a new position in Exact Sciences (EXAS) in Q1 2023: 10,500 shares worth $712K. The stake represents 0.94% of the portfolio and ranks #45 among its holdings.

582 funds tracked by Wall St. Rank hold EXAS as of Q1 2023.

Ascendant Capital Management held 10,500 shares of Exact Sciences worth $712K as of Q1 2023.
Exact Sciences was a new Ascendant Capital Management position in Q1 2023.
Exact Sciences made up 0.94% of Ascendant Capital Management's portfolio in Q1 2023, its #45 holding.
582 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2023.

Based on Ascendant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.